Exscientia Inc. (EXAI) - Price-to-Projected Revenue Ratio

Exscientia plc (EXAI) is a pioneer in applying AI to drug design for Big Pharma and startups. The projected P/S ratio helps assess the asset's value relative to expected sales, where the parameter value is 29.10. The company's prospects rely on clinical trials of oncology drugs and the use of neural networks to accelerate R&D in the US and UK in collaboration with global pharma behemoths.

EXAI Exscientia: Price-to-Projected Revenue Ratio in the range 07/04/2022 - 11/30/2024

EXAI (exscientia.ai): analytical breakdowns and indicator data

- stock price and consensus target price:

Stock Quotes Exscientia|EXAI - Fair Value Consensus

- market capitalization indicators:

Market Value Exscientia plc|EXAI - Full Business Value

- book value of equity indicators:

Net Assets per Single Share Exscientia|EXAI - Company Book Value|Market Capitalization to Book Value Ratio exscientia.ai|EXAI - Cumulative Company Assets

- debt burden and liquidity indicators:

- business earnings and investment ratios data:

EXAI - Net Profit|Projected Future Earnings Exscientia plc|EXAI - Business Payback Period|Forward P/E Multiple Exscientia|EXAI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Exscientia plc|EXAI - Operating profit before amortization|Earnings per share for the last twelve months Exscientia|EXAI - Net earnings per share for the last four quarters|Quarterly EPS earnings growth exscientia.ai|EXAI - Net earnings per share growth this year|Earnings growth forecast for next year Exscientia plc

- sales revenue and business income indicators:

EXAI - Company Gross Revenue|Projected Sales Volume Exscientia|EXAI - Price to Sales|Price-to-Projected Revenue Ratio Exscientia plc

Fundamental company valuation:Exscientia Inc. EXAI

Exscientia plc (EXAI) is consolidating the digital drug discovery market through a merger with an AI platform, which radically optimizes R&D costs. The ratio of market capitalization to projected revenue determines the value of future sales, allowing investors to assess whether the asset is overheated or trading at a discount by tracking the company's P/S expectations for a timely entry into the position.

Competitors of Exscientia plc

NVIDIA - Forward Price-to-Revenue Multiple|Forward Price to Sales CRWV|NBIS - Price-to-Projected Revenue Ratio|Future Price to Revenue SOUN|zetaglobal.com (ZETA) - Price-to-Projected Revenue Ratio|PGY (pagaya.com) - Price-to-Projected Revenue Ratio|AI (C3 AI) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Recursion Pharmaceuticals Inc (RXRX)|Forward P/S Multiple RZLV|SUPX - Market Cap to Future Revenue Ratio|Ginkgo Bioworks Holdings - Forward Price-to-Revenue Multiple|CRNC: Market Cap to Projected Revenue|Palladyne AI - Forward P/S Multiple|VERI - Forward P/S Multiple|MIMI: Forward P/S Multiple|MLGO - Market Cap to Expected Sales Ratio|HPAI (Helport AI Ltd.) - Forward P/S Multiple|Forward P/S Multiple liveperson.com|Forward P/S Multiple QUIK|Market Cap to Expected Sales Ratio system1.com|Forward P/S Multiple DVLT (WiSA Technologies)|Ruanyun Technology (RYET) - Market Cap to Future Revenue Ratio|WETO: Forward Price-to-Revenue Multiple|MCRP (micropolis.ai) - Market Cap to Projected Revenue|cyngn.com (CYN) - Price-to-Projected Revenue Ratio|YYAI - Market Cap to Expected Sales Ratio|HOLO (MicroCloud Hologram, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Infrared Cameras Inc. (MSAI)|Forward P/S Multiple EVAX|Market Cap to Expected Sales Ratio xiaoi.com|Forward P/S Multiple CXAI (CXApp)|BEN AI (BNAI) - Market Cap to Future Revenue Ratio|GXAI - Price-to-Projected Revenue Ratio|EVGN (Evogene Ltd.) - Market Cap to Projected Revenue|IFBD (infobird.com) - Forward Price-to-Revenue Multiple|TAOP: Price to Expected Revenue Ratio|VSAI (VERSES AI Inc.) - Forward P/S Multiple|foxotechnologies.com (FOXO) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VHAI|Forward P/S Multiple zapata.ai (ZPTA)